Abstract 511: Neratinib monotherapy in advanced non-small cell lung cancer with EGFR exon 18 mutations in China
Sign Up to like & getrecommendations! Published in 2025 at "Cancer Research"
DOI: 10.1158/1538-7445.am2025-511
Abstract: In NSCLC patients, EGFR exon 18 mutations account for approximately 3-5% and are associated with a poor prognosis. In phase 2 SUMMIT global trial, 29 metastatic NSCLC patients with EGFR exon 18 mutations received neratinib… read more here.
Keywords: exon mutations; cancer; egfr exon; neratinib monotherapy ... See more keywords